Vir Biotechnology director files initial Form 3

Vir Biotechnology, Inc. director Timothy Coughlin filed an initial Form 3 reporting his beneficial ownership of the company’s common stock.

Accepted by SEC EDGAR 06/10/2026 - 06:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vir Biotechnology, Inc. director Timothy Coughlin filed an initial Form 3 reporting his beneficial ownership of the company’s common stock. The filing shows he directly owns 0 shares of common stock following the reported position as of June 9, 2026.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Coughlin Timothy

Role Director

Type	Security	Shares	Price	Value
Holding	Common Stock	--	--	--

Holdings: Common Stock — 0 shares (Direct)

Key Figures

Common shares owned: 0 shares

1 metrics

Common shares owned 0 shares Total shares following reported position as of June 9, 2026

Key Terms

Form 3, beneficial ownership, Common Stock

3 terms

Form 3 regulatory

"director Timothy Coughlin filed an initial Form 3 reporting his beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"filed an initial Form 3 reporting his beneficial ownership of the company’s common stock"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Common Stock financial

"The filing shows he directly owns 0 shares of common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Timothy Coughlin’s Form 3 for Vir Biotechnology (VIR) show?

The Form 3 shows that director Timothy Coughlin reported beneficial ownership of 0 shares of Vir Biotechnology common stock as of June 9, 2026, indicating no directly owned position at that time.

Is Timothy Coughlin a director of Vir Biotechnology (VIR)?

Yes. The filing identifies Timothy Coughlin as a director of Vir Biotechnology, Inc. Directors are required to report their beneficial ownership of the company’s securities using SEC Form 3 when they become insiders.

How many Vir Biotechnology (VIR) shares does Timothy Coughlin report owning?

The filing reports that Timothy Coughlin directly owns 0 shares of Vir Biotechnology common stock following the reported position as of June 9, 2026, meaning no directly held common stock at that time.

Does Timothy Coughlin report any derivative securities in Vir Biotechnology (VIR)?

No derivative securities are listed. The derivativeSummary section is empty, and there are no option, warrant, or other derivative positions reported for Timothy Coughlin in this Form 3 filing.

Are there any buy or sell transactions in this Vir Biotechnology (VIR) Form 3?

No. The filing is categorized as a holding entry with an unknown transaction code and shows 0 shares owned. It does not report any purchases, sales, or exercises of Vir Biotechnology securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Coughlin Timothy

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026

3. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)